His figures sound real. I expect the initial negative impact on Copaxon's sales from Tecfidera's extra-forte strong launch to slow (my guess is that NRx is already up a bit from 25%). To what degree depends on how well patients will do on Tecfidera in the long run.
Market Data 
Markets 
AI
